Batalla A, García-Doval I, Aranegui B, García-Cruz A
Servicio de Dermatología, Complejo Hospitalario de Pontevedra, España.
Actas Dermosifiliogr. 2011 Sep;102(7):517-26. doi: 10.1016/j.ad.2010.12.011. Epub 2011 Mar 27.
References have been made in the literature to the funding of clinical trials by the pharmaceutical industry. Other types of funding, however, have been less well studied.
To describe the sources of funding for research by Spanish dermatology departments published in 2008.
A bibliometric study was performed of the research articles published by Spanish, French, and British dermatology departments and by Spanish rheumatology departments in 2008 according to MEDLINE records.
Articles published by Spanish dermatology departments received funding in 36.4% of cases. This percentage is lower than that found for the other groups studied and remained low for all different types of funding. Statistically significant relationships were found between a higher percentage of funding and a higher level of evidence, as well as between a higher level of funding by the pharmaceutical industry and the publication of research into quality of life and pharmacological treatment. Inadequate declaration of funding was observed in 57.1% of articles from Spanish dermatology departments and the role of the sponsor was not declared in any article. Similar findings were obtained for the other groups studied.
The proportion of research articles published by Spanish dermatology departments that receive external funding is low, and this is associated with a lower level of scientific evidence. In order to obtain more external funding, we must improve our competitiveness.